Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Inspirata Inks Separate Deals With Mikroscan, Augmentiqs

Inspirata Inks Separate Deals With Mikroscan, Augmentiqs

Mar 03, 2020
|
staff reporter

NEW YORK – Digital pathology firm Inspirata announced two deals Tuesday, one to market and distribute Mikroscan's digital pathology and telemicroscopy systems in the US, and one to partner with Augmentiqs to integrate its Dynamyx digital pathology workflow solution with augmented reality. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
23
Featured Webinar

Clinical Utility of Liquid Biopsy for the Detection of T790M to Guide Lung Cancer Treatment Strategy

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.

What's Popular?

In Cancer

  1. Burning Rock Bio, CStone Pharmaceuticals to Codevelop CDx for Pralsetinib in China

  2. Foundation Medicine Shifts Focus to Early Cancer Detection With Lexent Bio Acquisition

    Premium

  3. OncoCyte Downgraded to Neutral by Piper Sandler on Unsuccessful Results for Lung Cancer Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.